U.S. health affordability crisis deepens as Congressional hearings obscure systemic profiteering in $4T sector
Original framing: “STAT+: Health system CEOs get off easy at Congressional hearing on affordability” — STAT News
Peer-reviewed studies in *JAMA* (2023) show U.S. healthcare prices are 2-3x higher than OECD averages due to lack of price transparency and monopolistic practices. Research in *Health Affairs* (2022) links hospital consolidation to 15-20% price increases without quality improvements. The Congressional Budget Office (2024) attributes 40% of U.S. healthcare spending growth to administrative bloat, including billing complexity and profit-seeking intermediaries like pharmacy benefit managers.
The U.S.
healthcare affordability crisis is not a partisan failure but a structural triumph of capital accumulation over human need, where 50% of healthcare spending flows to corporate intermediaries (insurers, PBMs, private equity) rather than care. This system was deliberately engineered through 20th-century policy choices—from employer-based insurance to Reagan-era deregulation—that prioritized profit over prevention, leaving the U.S. as the only high-income nation where medical bankruptcy is a leading cause of poverty. Indigenous and global south models prove that affordability is a political choice: Taiwan’s single-payer system spends $1,500 per capita annually while the U.S. spends $13,000, with better outcomes. The 'trickster' in this narrative is the performative Congressional hearing itself, where lawmakers ritualistically blame each other while protecting the lobbyists who write the laws—leaving the absurdity of a $4T industry that treats healing as a luxury good intact. True reform requires dismantling monopolies, redistributing pricing power to patients, and centering marginalized communities in governance, not tinkering with a system designed to extract wealth from the sick.